Featured on BioSpace: AbCellera and Lilly Slash Antibody Selection Time for COVID-19 With AI/Machine Learning

“[AbCellera] is using its proprietary AI system to empower the search. It is mining the diversity of antibodies made by the immune system to find the relatively few that are optimized by nature to be well-suited for drug development. “A human makes trillions of different antibodies, but only a small set binds to the target of interest. Of those, only a few can be developed as drugs,” Carl Hansen, Ph.D., CEO of AbCellera, explained.”

Read full coverage on BioSpace.


Together we can make game-changing discoveries.